#IVD Devices | Explore Tumblr posts and blogs

mordorintelligencemarketresearch · 16 days ago

Text

Clinical Diagnostics Market is undergoing rapid transformation, driven by increasing focus on personalized medicine

Market Overview

The clinical diagnostics market is projected to be valued at USD 88.79 billion in 2025 and is expected to grow to USD 115.94 billion by 2030, registering a compound annual growth rate (CAGR) of 5.48% throughout the forecast period from 2025 to 2030. The clinical diagnostics market includes a variety of diagnostic tools and technologies, such as in-vitro diagnostic (IVD) devices, molecular diagnostics, imaging systems, laboratory tests, and point-of-care testing devices. These products are essential in healthcare settings for diagnosing infectious diseases, cancer, cardiovascular conditions, diabetes, genetic disorders, and other health conditions.

As healthcare systems increasingly focus on improving patient outcomes and reducing costs, clinical diagnostics has emerged as a cornerstone of preventive care, early disease detection, and personalized treatment approaches. The market is evolving with the integration of advanced technologies, including artificial intelligence (AI), machine learning, automation, and next-generation sequencing, which enhance diagnostic accuracy, speed, and efficiency.

Key Market Drivers

Several factors are contributing to the rapid growth of the clinical diagnostics market:

Rising Prevalence of Chronic and Infectious Diseases The global increase in chronic diseases, including diabetes, cardiovascular diseases, and cancer, has led to a growing need for diagnostic testing. Early and accurate detection of these conditions allows for timely interventions, improving patient outcomes. Additionally, the ongoing threat of infectious diseases, such as COVID-19, influenza, and tuberculosis, has significantly boosted the demand for diagnostic tests, particularly molecular and rapid diagnostic tests.

Technological Advancements in Diagnostics Advances in diagnostic technologies are revolutionizing the clinical diagnostics market. Innovations such as next-generation sequencing (NGS), molecular diagnostics, point-of-care (POC) testing, and digital health solutions are enabling faster, more accurate, and less invasive diagnostics. These technologies allow for real-time, remote, and high-throughput testing, which enhances the speed and efficiency of diagnosis, particularly in emergency and critical care settings.

Shift Toward Personalized Medicine Personalized medicine, which tailors treatment based on individual genetic makeup, is rapidly gaining traction in clinical care. This shift is driving demand for more sophisticated diagnostic tests, such as genetic tests, biomarkers, and companion diagnostics, which help healthcare providers determine the most effective treatment plans for patients based on their unique genetic profiles.

Growing Demand for Point-of-Care Testing Point-of-care (POC) testing refers to diagnostic tests conducted at or near the site of patient care, enabling rapid results and immediate decision-making. The demand for POC testing has increased due to its convenience, speed, and potential for reducing healthcare costs. With the increasing adoption of home testing kits, self-monitoring devices, and mobile health applications, the POC testing market is expected to continue expanding, particularly in remote and underserved areas.

Aging Population The global aging population is contributing significantly to the demand for clinical diagnostics. Older adults are more prone to chronic diseases, including diabetes, cardiovascular diseases, and cancer, all of which require ongoing diagnostic monitoring. As the elderly population grows, the need for regular diagnostic tests and screenings will continue to rise, further driving market growth.

Government Initiatives and Healthcare Investments Governments worldwide are investing in healthcare infrastructure and promoting preventive healthcare measures, which include the widespread adoption of diagnostic testing. Initiatives aimed at improving disease prevention, early detection, and access to healthcare services, especially in emerging markets, are fueling the demand for clinical diagnostics. Public health campaigns, screening programs, and disease-specific initiatives are also increasing the availability and utilization of diagnostic tests.

Market Segmentation

The clinical diagnostics market can be segmented based on product type, technology, application, and end-user:

By Product Type

In-Vitro Diagnostics (IVD): IVD products, which include reagents, test kits, and instruments, dominate the market. These are used in laboratories for the analysis of blood, urine, and other samples to detect diseases.

Point-of-Care (POC) Testing Devices: Devices used for on-site testing, providing rapid results in minutes. POC tests are increasingly used in emergency care, home health settings, and for chronic disease management.

Imaging Systems: Technologies such as X-rays, MRIs, CT scans, and ultrasound are commonly used in clinical diagnostics to provide visual information for the diagnosis of conditions such as cancer, cardiovascular diseases, and neurological disorders.

Molecular Diagnostics: Includes tests such as PCR, NGS, and other genetic tests used to diagnose diseases at a molecular level. This technology is especially critical for infectious diseases, cancer, and genetic disorders.

By Technology

Immunodiagnostics: These tests use antibodies or antigens to detect and monitor diseases. Immunoassays such as ELISA, lateral flow assays, and chemiluminescence are commonly used in clinical diagnostics.

Molecular Diagnostics: Technologies like polymerase chain reaction (PCR) and next-generation sequencing (NGS) are used to detect specific genetic material or mutations associated with diseases.

Clinical Chemistry: Laboratory tests that analyze blood, urine, and other body fluids to detect markers of disease or monitor conditions like diabetes and kidney disease.

By Application

Infectious Diseases: Testing for infectious diseases such as COVID-19, HIV, hepatitis, and tuberculosis has driven growth in molecular and rapid diagnostic testing technologies.

Cancer: Early detection and monitoring of cancer through biomarker testing, imaging, and genetic profiling are crucial for improving treatment outcomes.

Cardiovascular Diseases: Diagnostic tests for cardiovascular diseases, including cholesterol levels, ECGs, and echocardiograms, are widely used in clinical settings.

Diabetes: Diabetes diagnostics, including blood glucose tests, hemoglobin A1c tests, and continuous glucose monitoring devices, are growing in demand due to the rising prevalence of the disease.

By End-User

Hospitals and Clinics: Hospitals and clinical laboratories are the largest end-users of clinical diagnostic products due to the high volume of tests conducted in these settings.

Diagnostic Laboratories: Independent diagnostic laboratories and central labs play a key role in the diagnostic testing process, providing results for a variety of medical conditions.

Research and Academic Institutions: Research labs and universities conducting clinical trials and studies are major consumers of diagnostic technologies, particularly in the fields of genomics and molecular diagnostics.

Regional Analysis

The clinical diagnostics market is experiencing strong growth across various regions:

North America: North America holds the largest share of the clinical diagnostics market, driven by advanced healthcare infrastructure, high healthcare spending, and the adoption of cutting-edge diagnostic technologies. The U.S. is a key player in the global market, with strong demand for molecular diagnostics, immunodiagnostics, and imaging systems.

Europe: Europe is another significant market, with robust healthcare systems and increasing demand for early disease detection, personalized medicine, and point-of-care testing. Countries like Germany, the UK, and France are at the forefront of clinical diagnostics adoption in the region.

Asia-Pacific: The Asia-Pacific region is expected to see the highest growth rate, driven by expanding healthcare access, a growing aging population, and increasing investments in healthcare infrastructure. Countries like China and India are investing in diagnostic testing to improve disease detection and management.

Latin America & Middle East & Africa: These regions are witnessing increased demand for clinical diagnostics due to improving healthcare systems, government initiatives, and growing awareness of disease prevention. Emerging markets are becoming key growth areas for the industry.

Market Challenges

Despite the promising growth, the clinical diagnostics market faces several challenges:

Regulatory Hurdles The regulatory approval process for diagnostic tests can be lengthy and complex, especially for molecular diagnostics and new technologies. Navigating different regulatory environments in various regions can delay market entry for new products.

High Costs The cost of advanced diagnostic technologies, such as NGS, molecular diagnostics, and imaging systems, can be prohibitive, particularly in low- and middle-income countries. The high cost of testing also places a burden on healthcare systems, limiting access to diagnostic services in some regions.

Reimbursement Issues In many regions, diagnostic tests, particularly new or advanced technologies, may not be fully covered by insurance or public healthcare systems. This can limit the adoption of innovative diagnostic solutions, especially in cost-sensitive markets.

Future Outlook and Opportunities

The clinical diagnostics market is poised for significant growth in the coming years. Key opportunities include:

Integration of Artificial Intelligence (AI) The integration of AI and machine learning into diagnostic systems will enhance diagnostic accuracy, speed, and efficiency. AI can help analyze complex diagnostic data, enabling faster decision-making and improving patient outcomes.

Advancements in Molecular Diagnostics Molecular diagnostics, including NGS and PCR-based tests, will continue to drive market growth, especially in the detection of genetic disorders, cancers, and infectious diseases. The development of portable, rapid molecular diagnostics will further expand the market.

Expansion of Point-of-Care Testing The increasing adoption of POC testing solutions will provide opportunities for the market to grow, particularly in remote and underserved areas. Mobile health applications, at-home testing kits, and telemedicine solutions are expected to increase the accessibility of diagnostic services.

Personalized Medicine The rise of personalized medicine, driven by advances in genomics and biomarker testing, will create a demand for more sophisticated diagnostic tools to help tailor treatments to individual patients.

Conclusion

The clinical diagnostics market is undergoing rapid transformation, driven by technological advancements, rising disease prevalence, and an increasing focus on personalized medicine. As diagnostic tools become more accurate, accessible, and efficient, they will play an increasingly vital role in healthcare systems worldwide. The market offers vast growth potential, particularly in molecular diagnostics, point-of-care testing, and AI-driven solutions. While challenges remain, such as regulatory hurdles and high costs, ongoing innovation and investments will help address these issues and drive the market forward, ultimately improving patient care and outcomes.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence

#marketing #market size #market share

0 notes

global-research-report · 16 days ago

Text

The Evolving Flow Cytometry Market: Key Trends and Opportunities in 2025

The global flow cytometry market size is expected to reach USD 7.01 billion by 2030, registering a CAGR of 6.96% over the forecast period, according to a new report by Grand View Research, Inc. Technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (PoC) testing. Furthermore, the rising prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving the industry. In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments. In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.

Microfluidics and flow cytometry together make a useful tool to measure multiple characteristics of biological samples. For instance, the easy availability of several microfluidics and miniaturized detectors have enabled the creation of microchip-based cytometers, such as optofluidic cytometer, imaging cytometer, and impedance cytometer. The development of microfluidic flow cytometry devices, which are cost-effective, portable, and compact, is beneficial. They are affordable in developing economies, such as Asia & Africa, and are enabling rapid growth in PoC testing applications. Furthermore, improvements in fluorescent dyes and the increasing utility of benchtop cytometers for academic research settings are expected to drive the industry.

Developments in multicolor flow cytometry are accelerating the adoption of the technique in novel drug development activities. For instance, in January 2020, DxFLEX, CE-IVD, a 13-colour clinical flow cytometry system was launched by Beckman Coulter Life Sciences in Europe. Similarly, easy cellular analysis by simultaneous evaluation of several parameters allows extensive use of such devices for contract research purposes. The COVID-19 pandemic also spurred innovations in the technique, as evidenced by the launch of new products in this domain. For instance, in July 2021, Metropolis Healthcare Ltd. launched CoviRisk-TBNK, a simple blood test to detect the risk status of a COVID-19 hospitalized patient.

It helps analyze patients’ need for ICU facilities or ventilation and aids in the reduction of stress on healthcare resources. The test is a flow cytometry-based lymphocyte subset assay and is IVD-approved. Such innovations are anticipated to fuel industry growth in the near future. Moreover, flow cytometry is a significant tool in listing and characterizing immune cells, and is also helpful in recognizing and validating underlying genetic defects. The technique is also used to observe and monitor the immune response of patients after stem cell transplantation, and hence, organ transplantation plays an important role in boosting industry growth. According to the WHO, around 50,000 stem cell transplantations are performed globally every year, and this number is expected to grow in the near future, broadening the scope of applications for the technique.

On the other hand, instruments are highly expensive, and hence, buyers in several developing countries may not be able to afford technologically advanced flow cytometry equipment. These instruments may cost over USD 100,000 and pose significant budgetary constraints for small- & mid-sized hospitals and clinical laboratories. However, some manufacturers, such as Sony, are trying to launch newer instruments using software to automate a number of processes. Such developments would not only improve the usability of the technique but also help bring down the average instrumentation cost-under USD 100,000-in the near future.

Flow Cytometry Market Report Highlights

The instrument product segment held the largest share in 2023 due to technical advancements, as well as increased prevalence of chronic conditions

The cell-based flow cytometry technology dominated the industry in 2023 due to the high demand for early diagnosis and rising awareness about the associated benefits of cell-based assays

By application, the clinical segment accounted for the largest revenue share in 2023 owing to increased activities pertaining to infectious diseases, such as influenza, HIV, and COVID-19, among others

The academic institutes end-user segment led the market in 2023 owing to increased R&D activities by academic institutes & research centers

North America was the leading region in 2023 due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the region

Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 owing to the extensive growth in the pharmaceutical and biotechnology industries in emerging economies, such as China and India

Flow Cytometry Market Segmentation

Grand View Research has segmented the global flow cytometry market report based on product, technology, application, end-use, and region:

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Cell Analyzers

Cell Sorters

Reagents & Consumables

Software

Accessories

Services

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

Cell-based

Bead-based

Flow Cytometry Application Type Outlook (Revenue, USD Million, 2018 - 2030)

Research

PharmaceuticalApoptosis

Drug Discovery

Stem Cell

In Vitro Toxicity

Cell Sorting

Cell Cycle Analysis

Immunology

Cell Viability

Others

Industrial

Clinical

Cancer

Organ Transplantation

Immunodeficiency

Hematology

Autoimmune Disorders

Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 - 2030)

Commercial Organizations

Biotechnology Companies

Pharmaceutical Companies

CROs

Hospitals

Academic Institutes

Clinical Testing Labs

Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Canada

Europe

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Singapore

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players

Danaher

Sysmex Corporation

Agilent Technologies, Inc.

Apogee Flow Systems Ltd.

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

Stratedigm, Inc.

Miltenyi Biotec

Cytek Biosciences

Sony Group Corporation (Sony Biotechnology Inc.)

Order a free sample PDF of the Flow Cytometry Market Intelligence Study, published by Grand View Research.

#Flow Cytometry Market

0 notes

omcmedicalblog · 22 days ago

Text

Saudi Authorized Representative for Medical Devices | OMC Medical Limited

Medical device manufacturers aiming to enter the Saudi market must comply with the Saudi Food and Drug Authority (SFDA) regulations. For companies without a legal entity in the Kingdom of Saudi Arabia (KSA), appointing a Saudi Authorized Representative (Saudi AR) is a mandatory requirement. This post explores the responsibilities of a Saudi AR and the advantages of working with medical device regulatory consultants in Saudi Arabia.

Key Responsibilities of a Saudi AR

Device Registration and Approvals: Managing and submitting medical device and IVD registration applications to the SFDA, a vital step in the Saudi medical device registration process.

Fee Administration: Overseeing all SFDA-related fees on behalf of the manufacturer.

Post-Market Compliance: Reporting adverse events, coordinating recalls or Field Safety Corrective Actions (FSCA), and notifying the SFDA of device modifications.

Regulatory Communication: Serving as the primary point of contact with the SFDA, addressing inquiries, and ensuring compliance with Saudi Arabia medical device regulations.

Distributor Independence: Protecting intellectual property and allowing manufacturers to maintain control over distribution strategies in Saudi Arabia.

Why Choose Us?

Streamlined Registration Process. Regulatory Expertise in UAE Compliance. Cost-Effective & Timely Support.

Read full detailed article here: https://omcmedical.com/saudi-authorized-representative-for-medical-devices/

#saudimedicaldeviceregistration #sfda #saudimedicaldevicemarket

0 notes

regulatorysolutionsindia · 23 days ago

Text

How Regulatory Reporting Can Help in Medical Device Introduction in India

The Indian medical device market is growing at an unprecedented rate. Currently valued at approximately USD 12 billion, it is projected to reach USD 50 billion by 2030. This growth presents a lucrative opportunity for manufacturers and importers to introduce their medical devices in India.

However, entering this market requires careful navigation through stringent regulatory approval processes. To ensure a successful launch, having a robust plan for regulatory reporting is crucial.

In this blog, we will explain how regulatory reporting can assist in introducing a medical device in the Indian market.

Governing Body for Medical Device Registration in India

The Central Drugs Standard Control Organization (CDSCO) serves as the National Regulatory Authority of India, overseeing medical device registration and ensuring compliance with regulatory standards.

Who Can Apply for Medical Device Registration Under CDSCO?

The following parties are eligible to register medical devices with CDSCO:

Manufacturers with a registered office in India

Authorized representatives of the manufacturer

Subsidiaries of the manufacturer

Importers

Domestic manufacturers

For more information, refer to our blog, "7 Key Steps In CDSCO Medical Device Registration: Easy Guide."

What is Regulatory Reporting?

Regulatory reporting involves the systematic preparation and submission of documentation required for gaining approval to launch medical devices in the Indian market. This process is key to ensuring compliance with CDSCO regulations and other local standards.

Importance of Regulatory Reporting

Effective regulatory reporting facilitates:

Timely Market Access: Accelerating product approvals for quicker entry into the market.

Risk Minimization: Identifying and mitigating potential regulatory risks.

Regulatory Compliance: Ensuring adherence to evolving standards and regulations.

Resource Optimization: Enabling efficient allocation of resources during the approval process.

Key Components of Regulatory Reporting

A comprehensive regulatory reporting strategy consists of the following elements:

Product Type Identification Determine whether the product falls under medical devices, In Vitro Diagnostics (IVDs), cosmetics, or drugs, as each has distinct regulatory frameworks.

Risk Classification Establish the risk class of the device, as this impacts the regulatory requirements and approval pathway.

Existing Predicate or Similar Device Identify if a similar device exists in India. A predicate device demonstrates substantial equivalence and simplifies the approval process. If no predicate exists, additional steps are required. For more details, refer to our blog, "CDSCO Approval Process for Medical Devices Without Predicate in India."

Regulatory Status in Other Countries Leverage approvals from other countries to demonstrate safety, efficacy, and quality. This may also qualify the device for certain waivers, such as clinical trial exemptions.

Warehouse Availability & Registration Ensure that a warehouse is available and registered (Form MD-42). This is a mandatory prerequisite for introducing a medical device in India. Refer to our blog, "Registration Certificate for Sale," for further guidance.

Conclusion

The Indian medical device market presents tremendous opportunities but also demands adherence to stringent regulatory requirements. Comprehensive regulatory reporting ensures a clear pathway for product approval, minimizing delays and ensuring compliance.

Regulatory Solutions India (RSI) offers over 12 years of expertise in regulatory reporting, guiding companies through the complex process of medical device, IVD, cosmetics, and drug registration. Contact us today to streamline your product’s journey into India’s rapidly growing healthcare market. Partnering with RSI will help you bring your innovations to patients while ensuring compliance and commercial success.

#regulatory solutions india #Regulatory Report

0 notes

palashbhagat5 · 25 days ago

Text

0 notes

mmarketdbmr · 1 month ago

Text

0 notes

freyrsolutions · 2 years ago

Text

#Medical Devices #IVDs #EU IVDR #Class C IVDs #Regulatory Affairs #EU Regulations #European Union #EU #EU IVDR 2017/746

0 notes

pathologylab · 2 years ago

Photo

Experience the power of automation with Rapi-X 16- the ultimate #solution for fast and accurate nucleic acid #extraction. Our automated #system streamlines your workflow and ensures consistent results, every time. Say goodbye to a manual extraction and hello to effortless and efficient processing. Buy Now!! https://t2m.io/RAPI-Q-RTPCR For more details, Call us at 18001214030 or drop us an email at [email protected] for an appointment

#rapiq #diagnostics #rapid #kits #device #rtpcr #pcr #ivd #testing #genes2me #madeinindia #makeinindia #india #manufacturer #rnasequencing #dnasequencing #rna #dna #rtpcrkit #technology

0 notes

marketsndata · 2 months ago

Text

Japan In Vitro Diagnostics Market Analysis 2031

Japan In Vitro Diagnostics Market size was valued at USD 2.5 billion in FY2023 and is expected to reach USD 3.5 billion in FY2031 with a CAGR of 4.2% for the forecast period between FY2024 and FY2031.The Japan in vitro diagnostics (IVD) market has witnessed significant growth and innovation, solidifying its position as a crucial component in the healthcare sector. IVD refers to medical tests conducted on samples like blood, urine, and tissues outside the human body to diagnose diseases and conditions. This market has experienced steady expansion in Japan due to factors such as an aging population, rising healthcare awareness, and technological advances. The country’s aging demographic has contributed to an increased demand for accurate and efficient diagnostic tools, particularly for age-related diseases like cancer, diabetes, and cardiovascular conditions. This has propelled investments in research and development, creating cutting-edge IVD technologies that offer faster results and improved accuracy.

Japan’s commitment to technological advancement is evident in its adoption of automation, molecular diagnostics, and point-of-care testing. These advancements have streamlined diagnostic procedures, enabling quicker diagnoses and informed medical decisions. Additionally, collaborations between research institutions, healthcare providers, and industry players have fostered a conducive environment for innovation. Regulatory agencies like the Pharmaceuticals and Medical Devices Agency (PMDA) oversee the approval and quality control of IVD products, ensuring patient safety and product efficacy. Market players are focused on complying with these regulations while continuously refining their offerings. The Japan in vitro diagnostics market presents opportunities for domestic and international companies to contribute to the evolving healthcare landscape.

Advancement in Immunodiagnostics

In Japan, significant advancements in immunodiagnostics within the field of in vitro diagnostics have propelled healthcare efficacy. Cutting-edge technologies such as enzyme-linked immunosorbent assays (ELISAs), polymerase chain reaction (PCR) techniques, and flow cytometry have been integrated into diagnostic protocols, enabling rapid and accurate identification of various diseases. Collaborations between academia, industry, and research institutions have fostered the development of novel biomarkers and reagents for improved disease detection, monitoring, and personalized treatment. Additionally, automated platforms have streamlined laboratory processes, enhanced efficiency, and reduced turnaround times. The convergence of nanotechnology and immunodiagnostics has led to innovative biosensors capable of detecting minute biomolecular interactions with heightened sensitivity. Japan’s dedication to innovationand robust regulatory framework continue to drive the evolution of immunodiagnostic technologies, ultimately enhancing patient care through early and precise disease diagnosis.

In December 2022, bioMérieux unveiled the CE-mark approval for VIDAS KUBE, the advanced automated immunoassay system designed for the VIDAS product line.

Introduction of Latest Technologies

Japan is at the forefront of introducing cutting-edge technologies in vitro diagnostics (IVD). The nation’s innovation landscape showcases remarkable advancements such as microfluidic lab-on-a-chip systems, enabling rapid and accurate biomarker analysis with minimal sample volumes. Next-generation sequencing (NGS) applications have also gained traction, revolutionizing genetic and genomic testing by offering comprehensive insights into diseases. AI-driven diagnostic algorithms enhance precision and speed, aiding in early disease detection and personalized treatment strategies. Additionally, Japan has embraced point-of-care testing (POCT) devices that facilitate on-the-spot medical assessments, which are crucial for remote and resource-limited settings. These technologies not only bolster the efficiency of healthcare delivery but also contribute significantly to Japan’s position as a global leader in IVD innovation.

DiaCarta Inc., a molecular diagnostics company, declared in July 2022 that it had been granted the CE-IVD Mark for its recently developed QuantiVirus SARS-CoV-2 & Flu A/B test.

Enhanced Progress through Key Player Collaboration

The Japan in vitro diagnostics market experienced remarkable progress by fostering collaboration among key industry players. Manufacturers, researchers, and regulatory bodies collectively drove innovation, streamlined regulatory processes, and expedited product development by pooling resources, knowledge, and expertise. Collaborative efforts led to the creation of advanced diagnostic technologies, such as point-of-care testing and personalized medicine solutions, thus addressing Japan’s evolving healthcare needs. Sharing data and best practices improved diagnostic accuracy and accelerated the availability of cutting-edge tests for various diseases. Moreover, collaboration aided in aligning industry practices with regulatory requirements, ensuring timely market access for novel diagnostics.

In July 2021, Sysmex Corporation established a worldwide strategic partnership with QIAGEN N.V to collaborate on the advancement of cancer companion diagnostics.

Rise in Infectious Diseases

In Japan in vitro diagnostics market has witnessed a concerning surge in infectious diseases, prompting a heightened focus on in vitro diagnostics. This upswing can be attributed to increased global travel, urbanization, and evolving pathogens. In response, the Japanese healthcare system has intensified its reliance on in vitro diagnostics to identify infectious agents accurately and swiftly. These diagnostic tools encompass a range of technologies, including molecular assays, immunoassays, and nucleic acid testing, enabling healthcare professionals to diagnose infections and initiate appropriate treatments promptly. This emphasis on advanced diagnostics not only aids in efficient disease management but also plays a pivotal role in containing outbreaks and preventing their spread. As Japan grapples with the complexities of emerging infectious diseases, robust in vitro diagnostics serve as a cornerstone of its strategy to safeguard public health.

In April 2023, Oxford Nanopore Technologies plc and bioMerieux SA joined forces to improve global health results by investigating specific possibilities for introducing nanopore sequencing to infectious disease diagnostics.

Impact of COVID-19

As of March 23, 2022, more than 6.15 million individuals in Japan have been affected by the COVID-19 illness, with a corresponding death toll of 27,246. Throughout 2020, the growth of the Japan IVD (In Vitro Diagnostics) market was impeded by the COVID-19 pandemic, causing delays in routine procedures due to social constraints and precautionary measures. Nevertheless, with the gradual relaxation of social restrictions by governments, the downward trajectory in business revenues began to stabilize and reach a plateau before the onset of the third quarter in 2020. The global landscape remains overshadowed by the looming menace of novel coronavirus, wreaking havoc in the lives of countless individuals. Essential strategies for curbing its impact involve extensive testing and swift hospitalization to mitigate its spread. In this context, in-vitro diagnostics emerge as a pivotal element in ramping up testing efforts. Stakeholders within the in-vitro diagnostic market are diligently working on innovating novel technologies that enable widespread testing within a condensed timeframe.

As an example, during April 2021, Sysmex Corporation secured approval for in vitro diagnostics in Japan, enabling them to manufacture and market the Detect Amp SARS-CoV-2 RT-PCR Kit. This kit is designed to identify the RNA of the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19.

Download Free Sample Report

Report Scope

“Japan In Vitro Diagnostics Market Assessment, Opportunities and Forecast, FY2017-FY2031”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative & quantitative assessment of the current state of the In Vitro Diagnostics market, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, COVID-19, opportunities and forecast between FY2024 and FY2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/japan-in-vitro-diagnostics-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: [email protected] Website: https://www.marketsandata.com

#In Vitro Diagnostics #Japan Market #Market Research Reports #Market Updates

0 notes

global-research-report · 21 days ago

Text

The Future of Diagnostics: A Deep Dive into Point of Care Testing

The global point of care diagnostics market size is expected to reach USD 68.5 billion by 2030, registering a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of advanced technologies such as Telehealth enabled POCT is expected to fuel market growth. Furthermore, the rise in the geriatric population and their need for accessible home-based care are anticipated to drive the market.

The adoption of POCT in emerging economies such as Africa and Latin America is anticipated to be a growth determinant of the global POCT market. The authorities are decentralizing the healthcare system and increasing their investments. For instance, the African regulations in Kenya allotted USD 346.7 to Managed Equipment Services project for the government's initiative toward modernizing facilities by procuring new equipment. The Ministry of Health selected GE Health and Philips to offer equipment across 47 countries. Similarly, Latin America decentralized IVD testing, which encourages private players to take strategic initiatives to meet the region’s existing demand for affordable POCT, especially in the infectious diseases segment.

Currently developed POC devices and tests are employed across different medical diagnostic applications, including cancer, pregnancy, and infectious diseases. Patients and physicians employ POC tests to screen conditions, confirm diagnoses, and design suitable therapeutic approaches based on patient health. However, the enthusiasm displayed by different consumers, such as doctors, patients, and caregivers, varies widely. This dynamic consumption pattern of POC diagnostic products is also attributed to economic scalability, financial interests, and lack of a universal healthcare structure.

In the light of COVID-19, the lockdown imposed across the globe has necessitated virtual visits and rapid diagnostic tests that assist patients to avoid hospital visits. Post-lockdown, the eHealth strategy is the emerging area of priority and investment such as an automated patient appointment system, lab result transmission system, healthcare workers' communication system, and medical products procurement system for the companies and governments. It is anticipated to continue to prioritize home-based healthcare delivery even after the pandemic, especially for patients with pre-existing conditions. For instance, NeuroMetrix, Inc. appointed a team to develop the business of DPNCheck, a POCT for peripheral neuropathies. The team is responsible for expanding the footprint in the healthcare market and focusing on the Medicare Advantage population.

Point Of Care Diagnostics Market Report Highlights

The Infectious disease led the market and accounted for 27.8% of global revenue share in 2023. Growth of the segment is attributed to increasing demand for rapid tests, which has encouraged industry players to deliver point of care solutions to decentralized regions and launch innovative solutions.

Home sector is projected to witness the highest growth rate over the forecast period owing to the comfort level and cost-effectiveness of point of care diagnostics provided to patients at home. POCT devices are easy to use and do not, mandatorily, require any modern lab infrastructure for testing simpler target analytes in a patient's sample

North America dominated the market and accounted for a 42.9% share in 2023 owing to the increasing demand for new technologies, a large pool of key players, and advanced healthcare infrastructure

The Asia Pacific is anticipated to witness significant growth in the market owing to the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases. The increasing population with limited disposable income is the potential target market for the key players in the region

Point Of Care Diagnostics Market Segmentation

Grand View Research has segmented the global point of care diagnostics market on the basis of on product, end use, and region:

Point Of Care Diagnostics Product Outlook (Revenue, USD Billion, 2018 - 2030)

Glucose Testing

Hb1Ac Testing

Coagulation Testing

Fertility/Pregnancy

Infectious Disease

HIV POC

Clostridium Difficile POC

HBV POC

Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV) POC

HPV POC

Influenza/Flu POC

HCV POC

MRSA POC

TB and Drug-resistant TB POC

HSV POC

COVID-19

Other Infectious Diseases

Cardiac Markers

Thyroid Stimulating Hormone

Hematology

Primary Care Systems

Decentralized Clinical Chemistry

Feces

Lipid Testing

Cancer Marker

Blood Gas/Electrolytes

Ambulatory Chemistry

Drug of Abuse (DOA) Testing

Autoimmune Diseases

Urinalysis/Nephrology

Point Of Care Diagnostics End-use Outlook (Revenue, USD Billion, 2018 - 2030)

Clinics

Hospitals

Home

Assisted Living Healthcare Facilities

Laboratory

Point Of Care Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

Canada

Europe

Germany

France

Italy

Spain

Russia

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players of Point Of Care Diagnostics Market

Hoffmann-La Roche Ltd.

Qiagen

Danaher Corporation

Becton Dickinson (BD)

bioMérieux

Abbott

Siemens Healthcare GmbH

Werfen

Nova Biomedical

Trividia Health, Inc.

QuidelOrtho Corporation

Trinity Biotech

Sekisui Diagnostics

Orasure Technologies, Inc.

Spectral Medical, Inc.

EKF Diagnostics Holdings plc.

Anbio Biotechnology Co., Ltd.

AccuBioTech Co., Ltd

ALPHA LABORATORIES.

Order a free sample PDF of the Point Of Care Diagnostics Market Intelligence Study, published by Grand View Research.

#Point Of Care Diagnostics Market

0 notes

regulatorysolutionsindia · 25 days ago

Text

How Regulatory Reporting Can Help in Medical Device Introduction in India

However, entering this market requires careful navigation through stringent regulatory approval processes. To ensure a successful launch, having a robust plan for regulatory reporting is crucial.

In this blog, we will explain how regulatory reporting can assist in introducing a medical device in the Indian market.

Governing Body for Medical Device Registration in India

The Central Drugs Standard Control Organization (CDSCO) serves as the National Regulatory Authority of India, overseeing medical device registration and ensuring compliance with regulatory standards.

Who Can Apply for Medical Device Registration Under CDSCO?

The following parties are eligible to register medical devices with CDSCO:

Manufacturers with a registered office in India

Authorized representatives of the manufacturer

Subsidiaries of the manufacturer

Importers

Domestic manufacturers

For more information, refer to our blog, "7 Key Steps In CDSCO Medical Device Registration: Easy Guide."

What is Regulatory Reporting?

Importance of Regulatory Reporting

Effective regulatory reporting facilitates:

Timely Market Access: Accelerating product approvals for quicker entry into the market.

Risk Minimization: Identifying and mitigating potential regulatory risks.

Regulatory Compliance: Ensuring adherence to evolving standards and regulations.

Resource Optimization: Enabling efficient allocation of resources during the approval process.

Key Components of Regulatory Reporting

A comprehensive regulatory reporting strategy consists of the following elements:

Product Type Identification Determine whether the product falls under medical devices, In Vitro Diagnostics (IVDs), cosmetics, or drugs, as each has distinct regulatory frameworks.

Risk Classification Establish the risk class of the device, as this impacts the regulatory requirements and approval pathway.

Conclusion

#regulatory_reporting #Regulatory_solutions_india #RSI

0 notes

palashbhagat5 · 26 days ago

Text

0 notes

cailynnjohnson · 3 months ago

Text

From Lab-on-a-Chip to Industrial Innovation: Milestones in Microfluidic Technology

The global market for microfluidic products surged to $9.98 billion in 2019, with microfluidic devices accounting for $3.48 billion of this figure. A notable trend in the industry is the ongoing acquisition of microfluidic companies by larger enterprises, signaling a trajectory of accelerated growth through capital infusion.

In the industrial landscape, in vitro diagnostics (IVD) stands out as the primary sector for microfluidic applications, driven by its lucrative returns. Demographic shifts, particularly aging populations, contribute to an escalating demand for microfluidic chips. Moreover, governmental policies prioritize the advancement of the microfluidics industry, a focus that has intensified amidst the backdrop of the pandemic. Moving forward, the critical hurdles facing microfluidic chip technology revolve around manufacturing costs and scalability. Achieving scalable production processes and cost reduction measures while maintaining product standardization and minimizing variations are imperative objectives.

The evolution of modern technology emphasizes miniaturization, integration, and intelligence. Microelectromechanical systems (MEMS) have played a pivotal role in this evolution, enabling the transition from bulky electronic systems to compact integrated circuit chips and handheld devices like smartphones. Similarly, microfluidic chips, often referred to as Lab-on-a-Chip technology, epitomize the manipulation of fluids at micro- and nanoscales. These chips condense essential laboratory functionalities, such as sample preparation, reaction, separation, and detection, onto a compact chip, typically a few square centimeters in size. The hallmark of microfluidic chips lies in their capacity for flexible integration and scaling of diverse unit technologies within a controllable microplatform.

Originating from MEMS technology, early microfluidic chips underwent fabrication processes on substrates like silicon, metals, polymers, glass, and quartz. These processes yielded microstructure units such as fluid channels, reaction chambers, filters, and sensors, with dimensions ranging from micrometers to sub-millimeters. Subsequent fluid manipulation within these microstructures enabled automated execution of biological laboratory procedures, including extraction, amplification, labeling, separation, and analysis, or cell manipulation and analysis.

In the early 1990s, A. Manz et al. demonstrated the potential of microfluidic chips as analytical chemistry tools by achieving electrophoretic separation—a technique previously confined to capillaries—on chips. Subsequently, spurred by the U.S. Department of Defense's requisition for portable biochemical self-test equipment, research in microfluidic chips burgeoned globally. Throughout the 1990s, microfluidic chips primarily served as platforms for analytical chemistry, often interchangeably referred to as "Micro Total Analysis Systems" (u-TAS). Consequently, these chips found applications across diverse fields, including biomedical diagnostics, food safety, environmental monitoring, forensics, military, and aerospace sciences.

Key milestones in the advancement of microfluidic chips include G. Whitesides et al.'s 2000 publication on PDMS soft lithography and S. Quake et al.'s 2002 article on "large-scale integration of microfluidic chips" featuring microvalve and micropump controls. These seminal works propelled microfluidic chips beyond the confines of traditional analytical systems, unlocking their potential for significant scientific and industrial applications. For instance, microfluidic chips enable the execution of combinatorial chemical reactions or droplet techniques, facilitating drug synthesis, high-throughput screening, and large-scale nanoparticle or microsphere production. In essence, microfluidic chips pave the way for the realization of a "chemical plant or pharmaceutical lab on a chip."

#Lab-on-a-Chip

0 notes